Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC", Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company ("Fidelion") today announced the signing of a term sheet for a strategic, cross-equity partnership that the parties are calling a "DeepSeek-class leap" for liquid biopsy cancer monitoring and AI-driven biotechnology. This builds on BGLC's mission to be a global leader in liquid biopsies, and tumor naïve oncology solutions. Under the term sheet, BGLC will acquire a strategic equity stake in Fidelion and secure exclusive commercial rights to Fidelion's VitaGuard™ minimal-residual-disease (MRD) platform across Southeast Asia (ASEAN
KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit
KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The Company's 2024 report showcases a year of strategic realignment, technological advancement, and enhanced corporate governance - positioning BGLC for sustainable long-term growth. Financial Resilience and Market Stability BGLC ended 2024 with a strong cash position of over $4million and total l
10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)
NT 10-Q - BioNexus Gene Lab Corp (0001737523) (Filer)
8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit
SC 13G - BioNexus Gene Lab Corp (0001737523) (Subject)